泡上云霄前的轟隆轟隆  

The roar before the launch

大家新年好！

在即將即將來臨即將來臨2030年的美好生活一直，應當向列席職員和合作協議摯友們衷心謝謝我非常真誠的關心的話語和謝謝！

百利的2022年正是因為您們各個方面位的組織而美妙和太精彩。

新冠禽流的不選明確，使今年時間內始終是滿電成就的半年。但也所以那些成就和不選明確，要我們大家越發愈發團結合作、有力，不畏懼發展。

Hi Everyone,

I hope your holiday season is off to a bright start!

As 2021 draws to a close, I would like to take the opportunity to look back at some of my favorite moments from 2021, and express my sincere appreciation to our employees and our external partners. Without each one of you, we would not have been where we are today and together, we are building our company from the ground up. Thank you!

2021 is another year filled with challenges as we continue to experience the uncertainties of the COVID-19 pandemic. As we continue to navigate uncharted waters, we, as a close knit team with a mission to create are growing stronger as each day goes by.

…………………………………………………………………………………………………………………………………………………..

在百利與systimmune廣大干部公司員工的鍥而不舍努力奮斗下，他們的SEBA雙炎癥因子朋友免疫抗體陽性網上app、GNC多炎癥因子朋友免疫抗體陽性網上app、SHRI-ADC藥品網上app都作為了路程碑式的的提升。

未來三年時間內，我們大家早已有七個全國前沿的技術創新藥現已從診療上升入到診療現場實驗時期。是指雙抗SI-B001、SI-B003，四抗GNC-038、GNC-039、GNC-035，及雙抗ADC藥BL-B01D1，和SI-F019。

The entire team at SystImmune remained focused on innovative science in our drug development and our collaborative work with Baili’s R&D team has both deepened in the subject matters and widened in scope. As many of you know, this year marked a therapeutic milestone for our antibody drug conjugate capabilities. Importantly, we made major progress on the next generation development of GNC, which effectively solidified our leadership in multi-specific therapeutic antibody technology in oncology.

第1個開始臨床實踐護理理論研究探討的雙活性聊天抗原 SI-B001（EGFR X Her3）在111月開始了II期，并即將啟動服務器SI-B001與泰瑞沙（奧西替尼）連合醫療的臨床實踐護理理論研究探討產品。任何正當I 期試驗臺關鍵期的抗原性藥物，也都遵照明確計劃表盡早助推。

 Progressing from preclinical development into clinical trials is the result of our efficient Ｅxecution of a long-planned strategy. Currently, we have 7 molecules in Phase I or II clinical trials in China, including SI-B001, SI-B003, SI-F019, GNC-038, GNC-039, GNC-035, and BL-B01D1. Our first project, SI-B001, targeting EGFR and Her3 with a bispecific tetravalent, started enrollment for Phase II in December 2021, a pivotal milestone for oncology therapeutic testing. In addition, just a few days ago, we kicked off our collaborative relationship with AstraZeneca in connection with the clinical studying of SI-B001 in combination with TAGRISSO (osimertinib).

雙抗ADC中成藥BL-B01D1在9月新批IND 是你們的另外1個個里數碑，越來越指的喜悅的是，BL-B01D1都已經 于1二月在中山大學本科惡性腫瘤醫院醫生成功失敗入組第一名個病號。其次個ADC中成藥，BL-M02D1(Trop2)可能IND，第三種個ADC中成藥也將與此同時pre-IND。

The advanced approach of BL-B01D1 is our first bispecific ADC that received IND approval, which is another milestone. Not long after its IND approval in October, we accepted the first patient for the Phase I trial in December 2021. TROP2 specific agent is the second ADC in line and it is currently in pre-IND. All other active Phase I trials have shown no cause for safety related delays and are underway as planned. 

SI-B001也已在美式開始了報名IND，并還有機會于22年中可以獲得FDA的批復。美式醫學開放與醫學分析微商團隊的發展壯大任務也在準時來進行中。

As you may know, recently we have partnered with a U.S. based CRO to initiate our first US IND for SI-B001 drug. Our goal is to receive FDA approval of the IND around mid-2022. In the meantime, we have started to build up our U.S. clinical development team to bring in U.S. trial management capabilities onsite at SystImmune. With more clinical data to be generated and collected in 2022, we will be well position to advance our current research projects and to get closer to our mission of bringing new drugs and innovation to cancer treatment.

 ……………………………………………………………………………………………………………………………………………….

即便百利和Systimmune相隔一半地球表面，卻仍所以我門都有著雙方的目標--為肉瘤治療帶去攻克性的療效的創新發展藥，而輕輕地連通。要為收獲這般一中國智慧、專業化、講奉獻的管理團隊而到達欣慰。感觸我門也可以迅速談朋友，在下一里數碑光臨之刻，雙方舉杯邀歡慶。

感謝百利所有合作伙伴一直以來的支持和關心！

衷心感謝百利臨床醫學科研樓盤因此參研中央的每個科研者的歸屬感與回報！

感謝領導百利全員銷售人員在202在一年的嚴格要求自己和奮斗！

過年幸福快樂！期待已久小編會享有某個更迷人璀璨的22年！

I am so proud to have such a great team and I enjoy working with you all even though we are half a world apart. For those that I have not met in person, I am eager to know you more and to meet you in person next year. Your talent, work ethics, and your devotion to science and to our mission inspire me. 

At the same time, I would also like to thank our partners, including corporate attorney Qingqing, and our patent lawyer Dr. Connie Wang and Dr. Yangsong Gu, and our HR Taylor for their high quality professional services. 

Thank you again for all your effort and dedication in 2021. We look forward to another prosperous year in 2022. I wish you all a warm and healthy holiday season and a happy 2022. 

Sincerely,

Yi Zhu

President & CEO   

監事會成員長：朱義

2022年110月31日